Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Muscle Derived Stem Cells for Stress Urinary Incontinence
NCT02156934Phase 2Completed
- Sponsor
- Royan Institute
- Start
- Jan 2014
- Primary completion
- Dec 2015
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of AMDC-USR in stress urinary incontinence (SUI), sponsored by Royan Institute. Primary endpoint: 24-hour voiding diary reduction at 12 months. Started Jan 2014; status: completed.
02
Drugs
AMDC-USR
03
Conditions
stress urinary incontinence (SUI)
Beyond the preview
Go deeper on NCT02156934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02156934.